Neonatal hyperbilirubinemia. neonatal jundice, unspecified
Conditions
Interventions
Intervention 1: Intervention group: one 300mg ursodeoxycholic acid capsule (Abidi company) is dissolved in 10 cc sterile water.Then 1 cc of this solution is diluted with 5 cc sterile water and is giv
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Days to 7 Days
Inclusion criteria
Inclusion criteria: Body weight 2500-4000 gram Exclusive breast feeding Gestational age 38-41 weeks Total bilirubin 14-20 Direct bilirubin less than 2
Exclusion criteria
Exclusion criteria: ABO or Rh incompatibility Neonatal G6PD deficiency Sepsis symptoms Thyroid dysfunction Liver diseases Prematurity Maternal diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of the patients receiving unconjugated bilirubin 12, within 24 hours of admission. Timepoint: Unconjugated bilirubin level at the beginning of the study and every 12 hours to reach bilirubin 12. Method of measurement: Serum bilirubin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: Time interval of admission to discharge. Method of measurement: Checking hours of hospitalization.;Different side effects like diarrhea, vomiting, skin rash. Timepoint: Time interval of admission to 1 week after discharge. Method of measurement: History and physical exam.;Determining the percentage of patients receiving bilirubin 12, after 24 hours and before 48 hours of admission. Timepoint: 24 and 48 hours after being admitted. Method of measurement: Serum bilirubin. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactForouzan Rahimpour
Ahvaz University of Medical Sciences
Outcome results
None listed